Dr. Alex Zhavoronkov, Founder and CEO of Insilico Medicine, will attend the conference and deliver two high-profile sessions—a panel discussion alongside top industry experts on "AI's Race to Reinvent Medicine", and a solo keynote address exploring "How to Address Diseases and Aging Simultaneously Using Frontier AI".

Extreme fatigue, a racing pulse, shortness of breath, brain fog, aching joints—the symptoms of long COVID can vary widely, change unpredictably, and be difficult to even recognize as signs of the condition. Long COVID also remains difficult to treat, as no standard treatments yet exist. To develop better care for long COVID, scientists need to understand what drives it. But its complex landscape of symptoms arises from equally complex biological mechanisms that may differ considerably from patient to patient. At Gladstone Institutes, new tools and discoveries are rapidly filling in the blanks. Most recently, researchers in the lab of Nadia Roan, PhD, found evidence that people with long COVID have distinctive changes in immune cells specialized to protect against the virus that causes long COVID, alongside similar changes in cells that protect against two herpesviruses. The findings appear in Cell Reports Medicine.

The Alliance for Clinical Trials in Oncology today announced the activation of The QUANTUM Trial (Alliance A062401), a clinical study designed to test a novel, immune-targeting approach for patients newly diagnosed with primary plasma cell leukemia (PCL).